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INTRODUCTION
The duration of dual antiplatelet therapy (DAPT) in the drug-
eluting stent (DES) era remains controversial.1 Current clinical 
practice guidelines recommend the use of DAPT for 6 to 12 
months after DES implantation.2 However, in real-world prac-
tice, the use of DAPT for more than 12 months, the use of ex-
tended DAPT for more than 3 years, and nearly indefinite use 
of DAPT are common for various reasons. A recent large ran-
domized controlled trial indicated that the use of DAPT be-
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Purpose: Although current guidelines recommend the administration of dual antiplatelet therapy (DAPT) for up to 12 months af-
ter the implantation of a drug-eluting stent (DES), extended DAPT is frequently used in real-world practice. 
Materials and Methods: From the Korean Multicenter Angioplasty Team registry, we identified a total of 1414 patients who used 
DAPT for >3 years after DES implantation (extended-DAPT group) and conducted a landmark analysis at 36 months after the in-
dex procedure. We evaluated the determinants for and long-term outcomes of extended DAPT and compared the occurrence of 
major adverse cardiovascular and cerebrovascular events (MACCE), defined as the composite of all-cause death, myocardial in-
farction, stent thrombosis, and stroke, between the extended-DAPT group and the guideline-DAPT group [DAPT <1 year after DES 
implantation (n=1273)]. 
Results: Multivariate analysis indicated the occurrence of acute coronary syndrome as the most significant clinical determinant of 
the use of extended DAPT. Bifurcation, stent diameter ≤3.0 mm, total stented length ≥28 mm, and use of first-generation DESs were 
also significant angiographic and procedural determinants. MACCE rates were similar between the extended-DAPT group and the 
guideline-DAPT group in crude analysis [hazard ratio (HR), 1.08; 95% confidence interval (CI), 0.69–1.68; p=0.739] and after pro-
pensity matching (HR, 1.22; 95% CI,  0.72–2.07; p=0.453). Major bleeding rates were comparable between the two groups. 
Conclusion: In patients undergoing percutaneous coronary intervention, indefinite use of DAPT does not show superior out-
comes to those of guideline-DAPT. Major bleeding rates are also similar.
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yond 1 year after DES implantation significantly reduced the 
risk of stent thrombosis (ST) and major adverse events, but 
increased the risk of bleeding, which was associated with an 
increase in mortality.3 Therefore, we sought to investigate the 
major clinical, angiographic, and procedural determinants for 
extended-DAPT use (DAPT >3 years), and to compare the 
long-term clinical outcomes between patients who used DAPT 
for more than 3 years and those who used DAPT for up to 12 
months. 
MATERIALS AND METHODS
Between April 2003 and March 2012, patients who underwent 
percutaneous coronary intervention (PCI) using DESs and 
met the study criteria were enrolled in the Korean Multicenter 
Angioplasty Team registry.4 A total of a 4081 patients were iden-
tified for analysis after excluding patients with the following 
conditions: 1) major adverse events such as death, myocardial 
infarction (MI), ST, repeated revascularization, stroke, or ma-
jor bleeding; 2) clinical follow-up duration of <3 years; and 3) 
unclear DAPT duration (Fig. 1). Patients were classified into 
three groups according to DAPT duration after DES implanta-
tion as follows: patients who used DAPT for more than 3 years 
(extended-DAPT group; n=1414); patients who used DAPT for 
1–3 years (intermediate-DAPT; n=1394); and patients who dis-
continued DAPT and switched to single antiplatelet therapy 
within 12 months according to clinical guidelines (guideline-
DAPT group; n=1273). To evaluate the major determinants for 
long-term outcomes of extended DAPT use, various baseline 
clinical, angiographic, and procedural characteristics and clin-
ical outcomes of the extended-DAPT group were compared to 
those of the guideline-DAPT group. To compare the clinical 
outcomes, a landmark analysis was performed 3 years after the 
index procedure. In this study, DAPT was defined as the com-
bination of aspirin and clopidogrel, and patients who received 
other P2Y12 inhibitors were not included. The Institutional 
Review Board or ethics committee approved the study proto-
col (4-2018-0759), and all patients provided written informed 
consent before participating in the study.
Data were recorded using standard case report forms, and 
procedural angiographies were forwarded to the coordinating 
center. Baseline clinical and angiographic data were collected 
for all patients, including age, sex, traditional coronary risk 
factors, past medical history, and clinical presentation. 
Follow-up included visits to the outpatient clinic at 30 days 
and 3 months after the procedure and every 3 to 6 months there-
after. Patients who were lost to regular clinical follow-up were 
contacted by telephone and asked about their clinical status. 
The primary endpoints were 1) major clinical, angiographic, 
and procedural determinants for extended-DAPT use (DAPT 
>3 years) and 2) the occurrence of major adverse cardiovas-
cular and cerebrovascular events (MACCE), defined as the 
composite of all-cause death, MI, ST, and stroke. The second-
ary endpoints were 1) net adverse clinical events (NACE), de-
fined as the composite of all-cause death, MI, ST, stroke, and 
major bleeding; 2) the composite of cardiac death, MI, and 
ST; and 3) individual components of MACCE and NACE.
All events were defined according to the Academic Re-
search Consortium and an expert consensus document that 
defined the third universal definition for MI.5,6 Deaths were 
classified as being due to cardiac or noncardiac causes.5 MI 
was defined as a creatine kinase myocardial band fraction ele-
vation above the upper limit of normal (ULN) or troponin T/I 
>99th percentile of the ULN, with concomitant ischemic 
symptoms, electrocardiographic findings, or abnormal imag-
ing findings indicative of myocardial ischemia unrelated to an 
interventional procedure.5,6 ST was defined as definite or prob-
able ST.5 Stroke was defined as brain cell death caused by isch-
emia based on pathological, imaging, or other objective evi-
dence of cerebral focal ischemic injury in a defined vascular 
distribution or clinical evidence of cerebral focal ischemic in-
jury based on symptoms persisting ≥24 hours or until death; 
other etiologies were excluded.7 Strokes were determined to be 
either hemorrhagic or ischemic using imaging studies. Major 
bleeding was defined as type 3 or 5 according to the Bleeding 
Academic Research Consortium criteria.8 Congestive heart fail-
ure was defined as left ventricle ejection fraction <40%.9 Bifur-
cation lesions were defined as Medina classification (1.1.1), 
(1.0.1), or (0.1.1) lesions.10 The DAPT scoring system assigned 
1 point each for MI at presentation, prior MI or PCI, diabetes, 
stent diameter <3 mm, cigarette smoking, and paclitaxel-elut-
ing stent; 2 points each for the history of congestive heart fail-
ure/low ejection fraction (<30%) and vein graft intervention; 
-1 point for age 65–75 years; and -2 points for age ≥75 years.11 
Continuous variables are expressed as a mean±standard 
deviation, and categorical data are presented as frequencies. For 
group comparisons, Pearson’s chi-square test, Fisher’s chi-exact 
test, or Wilcoxon rank-sum test were used, as appropriate. Time-
to-event data are presented using Kaplan-Meier estimates. The 
rates for each event during the follow-up period were analyzed 
using Kaplan-Meier method. Log-rank test was used to com-
pare survival rates. Hazard ratios (HR) with 95% confidence 
intervals (CI) were estimated from a Cox proportional hazards 
model. To identify the determinants for the use of extended-
DAPT, we performed univariate and multivariate analyses. 
Any variable with p value<0.10 in univariate analysis was in-
cluded in the multivariate models. To reduce bias between 
the two groups in comparison, propensity score matching was 
used. Propensity score adjusting was used in the logistic re-
gression models, with DAPT continuation at 36 months used 
as the dependent variable along with 27 independent vari-
ables. A two-sided p value<0.05 was considered statistically 
significant. Statistical analyses were performed using SPSS 
statistical software (SPSS version 23.0 for Windows, IBM Corp., 
Armonk, NY, USA).
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RESULTS
Among the eligible patients (n=4081), 1414 (34.6%) were in-
cluded in the extended-DAPT group and 1273 were included in 
the guideline-DAPT group (Fig. 1). The baseline clinical charac-
teristics of both groups are presented in Table 1. Compared to 
the guideline-DAPT group, the extended-DAPT group had 
higher incidences of prior MI, PCI, and bypass surgery; and 
acute coronary syndrome (ACS); and a lower left ventricular 
ejection fraction. 
Angiographic and procedural characteristics are provided 
in Table 2. Compared to the guideline-DAPT group, the extend-
ed-DAPT group had higher proportions of individuals with le-
sions with multi-vessel disease, in-stent restenosis, bifurca-
tion, and number of lesions treated ≥2. The extended-DAPT 
group had a greater number of stents implanted, longer- and 
smaller-sized stents used, and a more frequent use of first-gen-
eration DESs compared to the guideline-DAPT group. 
DAPT scores were higher in the extended-DAPT group than 
in the guideline-DAPT group (p<0.01), and the proportion of 
patients with DAPT scores greater than 2 points was higher in 
the extended-DAPT group (50.3% vs. 29.3%, p<0.01) (Supple-
mentary Table 1, only online).
In multivariate analyses for the determinants of extended use 
of DAPT, ACS presentation was the most significant clinical 
Table 1. Clinical Characteristics 
Characteristics Extended-DAPT (n=1414) Guideline-DAPT (n=1273) p value
Age (yr) 62.8±9.8 62.7±9.9 0.809
Male 927 (66) 858 (67) 0.456
Body mass index (kg/m2) 24.8±3.0 24.8±2.9 0.950
Current smoker 308 (22) 301 (24) 0.249
Dyslipidemia or statin use before procedure 1160 (82) 1057 (83) 0.498
Hypertension 879 (62) 808 (64) 0.484
Diabetes mellitus 447 (32) 387 (30) 0.498
Chronic kidney disease 39 (3) 23 (2) 0.101
Congestive heart failure 38 (3) 27 (2) 0.340
Left ventricular ejection fraction (%) 57.8±13.4 61.4±12.3 <0.001
Prior stroke 116 (8) 107 (8) 0.850
Prior myocardial infarction 157 (11) 71 (6) <0.001
Previous percutaneous coronary intervention 265 (19) 136 (11) <0.001
Prior bypass surgery 59 (4) 35 (3) 0.045
Clinical presentation <0.001
Acute coronary syndrome 652 (46) 492 (39)
Acute myocardial infarction 301 (21) 249 (20)
Unstable angina 351 (25) 243 (19)
Stable angina 762 (54) 781 (61)
Medications at discharge
β-blockers 849 (60) 741 (58) 0.330
Angiotensin-converting enzyme or angiotensin-receptor blockers 789 (56) 724 (57) 0.583
Statin 1376 (97) 1235 (97) 0.642
DAPT, dual antiplatelet therapy.
Data are presented as the mean±SD or percentage (%). 
Exclusion







2744 follow-up duration <3 years
365 unclear duration of DAPT
Korean Multicenter Angioplasty Team registry 
(n=7403)
4081 free from MACCE for 3 years
Long-term clinical follow-up
Intermediate-DAPT group






Fig. 1. Study at a glance. DAPT, dual antiplatelet therapy; MACCE, major 
adverse cardiovascular and cerebrovascular events.
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determinant. Of the angiographic and procedural variables, 
bifurcation, total stent length ≥28 mm, stent diameter ≤3.0 
mm, and use of first-generation DESs were significant deter-
mining factors for the extended use of DAPT (Table 3).
During follow-up (median duration, 120 months), there were 
79 MACCEs (2.9%; 36 all-cause deaths, 29 MI, 6 ST, 22 strokes) 
after DES implantation, and no significant difference was not-
ed between the extended-DAPT and guideline-DAPT groups 
in both the crude- and propensity-matched analyses (Table 4 
and Fig. 2). The rates of MACCE and NACE were not signifi-
cantly different between the two groups in either the crude- 
or propensity-matched analyses. The rates of composite all-
cause death, MI, and ST were also not significantly different 
between the two groups in both the crude- and propensity-
matched analyses. The rates of major bleeding were similar be-
tween the two groups (p=0.185). In propensity-matched analy-
ses, the extended-DAPT group showed a trend toward having 
a higher major bleeding rate compared to the guideline-DAPT 
group, although the difference was not statistically significant 
(p=0.070)
We also performed subgroup analyses while focusing on the 
major determining factors for extended-DAPT (Fig. 3). In the 
subgroup analyses of composite of all-cause death, MI, and ST, 
a significant interaction was not noted. In multivariate analy-
sis for the composite of all-cause death, MI, and ST, age (per 
year) and total stent length ≥28 mm were significant risk fac-
tors (Supplementary Table 2, only online).
DISCUSSION
The principal findings of the current study are as follows: 1) In 
real-world practice, extended DAPT is frequently used in pa-
tients without MACCE and with DES implantation (approxi-
mately 1/3 of patients). 2) Significant determinants for the ex-
tended use of DAPT for more than 3 years were ACS, bifurcation, 
small diameter and long length of DES, and use of first-genera-
tion DESs. 3) In patients undergoing PCI, the outcomes after 
extended-DAPT, defined as indefinite use of DAPT with aspi-
rin and clopidogrel, did not show superiority over those after 
the guideline-DAPT, and major bleeding rates were similar. 
4) In patients treated with first-generation DESs, extended use 
of DAPT was significantly associated with lower MACCE rates 
compared to the use of guideline-DAPT.
Antiplatelet treatment is a cornerstone in the management 
of patients with DES implantation for preventing ST.2 Howev-
er, even with the designated duration recommended in cur-
rent guidelines, the optimal DAPT duration after DES implan-
tation still remains debatable.3,12,13 Both prolonged DAPT for 
longer than 1 year and short-term DAPT for 3–6 months have 
been proposed. A recent randomized DAPT trial demonstrat-
ed that the use of DAPT beyond 1 year after the placement of 
a DES significantly reduced the risks of ST (1.4% vs. 0.4%) and 
MACCE (5.9% vs. 4.3%) compared to using aspirin therapy 
alone. A previous meta-analysis also indicated that DAPT for 
1 year after DES implantation reduced the occurrence of MI 
and ST, but increased mortality due to an increased risk of 
non-cardiovascular mortality.14 In the current real-world reg-
istry study, 34.6% of patients who had not experienced MAC-
CE for 3 years still received DAPT at 3 years. Similarly, the pat-
terns of nonadherence to antiplatelet regimens in stented 
patients (PARIS) registry investigating DAPT patterns in post-
PCI patients indicated that 42.0% of patients were still receiv-
ing DAPT at 2 years.15 Thus, there appear to be some conflict 
between the guideline recommendations and the actual use 
in recent clinical trials. In addition, the incidence and determi-
nants for the extended use of DAPT have not been clearly es-
tablished in real-world practice.
Many scoring systems have been suggested for determining 
the duration of DAPT.11,16,17 In particular, DAPT, PARIS, and the 
Predicting Bleeding Complications In Patients Undergoing 









Multi-vessel (2- or 3-vessel) disease 980 (69) 742 (58) <0.001
Treated vessel 0.596
Left anterior descending 813 (58) 761 (60)
Left circumflex 227 (16) 184 (15)
Right coronary 365 (26) 320 (25)
Graft 9 (1) 8 (1)
Left main artery involvement 121 (9) 112 (9) 0.825
Chronic total occlusion 71 (6) 57 (5) 0.243
In-stent restenosis 69 (9) 30 (3) <0.001
Bifurcation 385 (50) 366 (36) <0.001
Calcification (moderate or severe) 131 (11) 127 (11) 0.853
Number of lesions treated ≥2 549 (39) 345 (27) <0.001
Total number of stents implanted 1.6±0.7 1.5±0.6 <0.001
Total stent length 40.5±21.3 32.8±17.6 <0.001
Total stent length ≥28 mm 968 (69) 675 (53) <0.001
Stent diameter 3.0±0.4 3.1±0.4 <0.001
Stent diameter ≤3.0 mm 1106 (78) 571 (45) <0.001
Type of drug-eluting stents <0.001
First-generation 1078 (76) 313 (25) <0.001
Sirolimus-eluting 762  256
Paclitaxel-eluting 316 57




Mixed use of the first- and 
  second-generation
67 (5) 28 (2)
Glycoprotein IIB/IIIA blocker use 21 (4) 20 (3) 0.391
DAPT, dual antiplatelet therapy.
Data are presented as the mean±SD or percentage (%).
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Stent Implantation and Subsequent Dual Antiplatelet Therapy 
(PRECISE-DAPT) score have focused on clinical determinants 
for the optimal duration of DAPT. In the current study, the 
proportion of patients with a DAPT score of more than 2 points 
was significantly higher in the extended-DAPT group, and the 
initial clinical presentation of ACS was the most significant 
clinical factor that determined the duration of DAPT. Indeed, 
previous studies have reported that the use of extended DAPT 
in ACS patients reduces recurrent ischemic events, and that a 
significant proportion of patients experience adverse cardiac 
events beyond the first year after ACS.18
Lesion- or procedural-complexity could be considered when 
determining DAPT duration. However, these are not consid-
ered in the current scoring systems that are used to determine 
DAPT duration. In contrast, lesion- and procedural-complexi-
ty were identified as major determinants for the use of extend-
ed DAPT in this study. Stent-related predictors were also sig-
nificant determining factors for DAPT duration. In the current 
study, the total stented length of ≥28 mm, minimal stent di-
ameter of ≤3.0 mm, and the use of first-generation DES were 
major determining factors. Previous meta-analyses indicated 
that the most significant predictors of ST include longer stent 
length [odds ratio (OR), 1.3; 95% CI, 1.2–1.5, per 10 mm] and 
final minimal lumen diameter with stent (OR, 04; 95% CI, 0.2–
0.7, per 1 mm).19 Another study on the etiology of very-late ST 
also indicated that patients with very-late ST had longer le-
sions and stents.20 Therefore, physicians tend to use extended 
DAPT. A significant angiographic predictor in this study was 
the occurrence of a bifurcation lesion. This may have been re-
lated to the increasing concerns caused by a higher risk of ST 
after the use of the two-stent technique or malapposed metal 
burden in the jailed side branch from the use of a cross-over 
single stent. A previous study reported that the risk of all-
cause death or MI was significantly lower in the ≥12-month 
DAPT group than in the <12-month DAPT group after PCI for 
bifurcation lesions using DES.21 
Table 3. Univariate and Multivariate Analyses of Determinants for the Extended Use of DAPT
Variables
Univariate analysis Multivariate analysis*
OR (95% CI) p value OR (95% CI) p value
Clinical variables
Age (yr) 1.00 (0.99–1.01) 0.809 1.00 (0.98–1.01) 0.462
Body mass index (kg/m2) 1.01 (0.97–1.03) 0.950
Male 1.06 (0.90–1.25) 0.456 1.26 (0.95–1.67) 0.114
Hypertension 0.95 (0.81–1.11) 0.484
Diabetes mellitus 1.06 (0.90–1.25) 0.498
Chronic kidney disease 1.54 (0.92–2.60) 0.103
Current smoker 0.90 (0.75-–1.08) 0.250
Acute coronary syndrome presentation 1.38 (1.18–1.61) <0.001 1.37 (1.06–1.79) 0.018
Prior percutaneous coronary intervention 1.93 (1.54–2.41) <0.001 1.43 (0.92–2.21) 0.113
Prior bypass surgery 1.54 (1.01–2.36) 0.047 1.22 (0.59–2.53) 0.598
Prior myocardial infarction 2.12 (1.58–2.83) <0.001 1.55 (0.96–2.49) 0.072
Prior heart failure 1.27 (0.77–2.10) 0.341
Prior stroke 0.97 (0.74–1.28) 0.850
Angiographic variables
Treated lesion number ≥2 1.71 (1.45–2.01) <0.001 0.91 (0.65–1.30) 0.613
Multivessel disease 1.62 (1.38–1.89) <0.001 1.16 (0.85–1.58) 0.345
Left main involvement 0.97 (0.74–1.27) 0.825
In-stent restenosis 3.38 (2.18–5.24) <0.010 2.04 (0.99–4.20) 0.053
Bifurcation 1.78 (1.47–2.15) <0.001 1.55 (1.19–2.02) 0.001
Chronic total occlusion 1.24 (0.87–1.77) 0.244
Procedural variables
Total stent length ≥28 mm 1.92 (1.64–2.25) <0.001 1.54 (1.12–2.12) 0.007
Stent diameter ≤3.0 mm 4.42 (3.73–5.22) <0.001 3.33 (2.51–4.43) <0.001
First-generation drug-eluting stents 11.91 (9.93–14.29) <0.001 11.43 (8.78–14.87) <0.001
DAPT, dual antiplatelet therapy; OR, odds ratio; CI, confidence interval.
*Any variable with p<0.10 in univariate analysis was included in the multivariate models. 
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Table 4. Clinical Outcomes at 10 Years (Median Follow-Up Duration)
Crude analysis Extended-DAPT (n=1414) Guideline-DAPT (n=1273) HR (95% CI) p value
Follow-up duration (month) 111.11±18.8 103.0±18.0
MACCE (all-cause death, MI, ST, and stroke) 44 (3.3) 35 (3.2) 1.08 (0.69–1.68) 0.739
NACE (all-cause death, MI, ST, stroke, and major bleeding) 60 (4.7) 43 (4.4) 1.10 (0.74–1.64) 0.629
Composite of all-cause death, MI, and ST 32 (2.4) 30 (2.8) 0.91 (0.55–1.49) 0.700
Death 22 (1.7) 14 (1.4) 1.31 (0.67–2.56) 0.434
Cardiovascular death 2 (0.1) 4 (0.4) 0.41 (0.07–2.24) 0.303
Non-cardiovascular death 20 (1.5) 10 (1.0) 1.67 (0.78–3.58) 0.186
MI 14 (1.1) 15 (1.3) 0.80 (0.39–1.66) 0.553
ST 3 (0.2) 3 (0.3) 0.84 (0.17–4.19) 0.832
Total stroke 13 (1.0) 9 (0.8) 1.25 (0.53–2.92) 0.611
Ischemic stroke 11 (0.8) 8 (0.7) 1.18 (0.47–2.94) 0.726
Hemorrhagic stoke 2 (0.1) 3 (0.3) 0.60 (0.10–3.56) 0.569
Major bleeding 19 (1.5) 9 (1.2) 1.71 (0.77–3.80) 0.185
Propensity score matching analysis Extended DAPT (n=677) Guideline DAPT (n=1149) HR (95% CI) p value
Follow-up duration, months 108.4±21.7 102.8±18.4
MACCE (all-cause death, MI, ST, and stroke) 24 (3.8) 33 (3.2) 1.22 (0.72–2.07) 0.453
NACE (all-cause death, MI, ST, stroke, and major bleeding) 36 (6.1) 39 (4.2) 1.43 (0.90–2.25) 0.128
Composite of all-cause death, MI, and ST 16 (2.5) 28 (2.8) 0.96 (0.52–1.78) 0.895
Death 12 (1.9) 13 (1.3) 1.51 (0.69–3.31) 0.306
Cardiovascular death 1 (0.2) 4 (0.5) 0.39 (0.04–3.52) 0.402
Non-cardiovascular death 11 (1.8) 9 (0.8) 2.02 (0.84–4.88) 0.119
MI 7 (1.1) 14 (1.4) 0.84 (0.34–2.09) 0.713
ST 2 (0.3) 3 (0.3) 1.07 (0.18–6.42) 0.944
Total stroke 8 (1.3) 8 (0.8) 1.64 (0.61–4.39) 0.324
Ischemic stroke 8 (1.3) 8 (0.8) 1.64 (0.61–4.39) 0.324
Hemorrhagic stoke 0� 0� - -
Major bleeding 12 (2.1) 8 (1.2) 2.29 (0.93–5.63) 0.070
DAPT, dual antiplatelet therapy; HR, hazard ratio; CI, confidence interval; MACCE, major adverse cardiovascular and cerebrovascular events; NACE, net adverse 
clinical events; MI, myocardial infarction; ST, stent thrombosis.
Data are presented as the mean±SD or number (%) and percentages, along with Kaplan-Meier estimates.  
Fig. 2. Cumulative MACCE rates according to Kaplan-Meier analyses. (A) Crude-analysis. (B) Propensity score matching analysis. DAPT, dual anti-
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Extended-DAPT vs. Guideline-DAPT, 3.3% vs. 3.2%
HR, 1.08 (95% CI, 0.69–1.68), Log rank p=0.74
Extended-DAPT vs. Guideline-DAPT, 3.8% vs. 3.2%
HR, 1.22 (95% CI, 0.72–2.07), Log rank p=0.45
  Extended-DAPT group
  Guideline-DAPT group
  Extended-DAPT group
  Guideline-DAPT group
No. at risk                         Years No. at risk                         Years
Extended-DAPT 1414 1375 1342 1302 1252 1204 1118 974
Guideline-DAPT 1273 1241 1216 1179 1131   930   589 342
Extended-DAPT   677   647   622   600   576   552   502 409
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The type of DES was also a significant determining factor 
for the extended use of DAPT. Some registry data have indi-
cated a continually increasing risk of ST several years after 
first-generation DES implantation.22 Currently available regis-
try data suggest a lower rate of ST in patients who received sec-
ond-generation DESs compared to those who received first-
generation DESs.23 In the patients who received first-generation 
DESs in this study, there was a lower rate of MACCE in the ex-
tended-DAPT group compared to the guideline-DAPT group. 
A previous study (ARTIC-Generation; Clinical Outcome of 
First- vs. Second-Generation DES According to DAPT Dura-
tion) also indicated worse clinical outcomes with first-genera-
tion DESs compared to second-generation DESs, a difference 
that appeared to persist even with prolonged DAPT (6.2% vs. 
2.6%; HR, 2.31; 95% CI, 1.31–4.07; p=0.004).24 In the current 
study, extended DAPT use led to a significant reduction in MAC-
CE in patients who were treated with first-generation DESs. 
Based on the results of this study and other studies, extended 
DAPT could be carefully considered for patients treated with 
first-generation DESs. 
There are several concerns regarding extended DAPT, such 
as increased major bleeding [ARCTIC-Interruption (Dual-An-
tiplatelet Treatment beyond 1 Year after Drug-Eluting Stent 
Implantation): 12-month vs. 18–30 month DAPT, <0.5% vs. 1%, 
p=0.073; DAPT: 12-month vs. 30-month DAPT, 1.6% vs. 2.5%, 
p=0.001; PRODIGY (Prolonging Dual Antiplatelet Treatment 
After Grading Stent-Induced Intimal Hyperplasia Study): 24- 
month vs. 6-month DAPT, 7.4% vs. 3.5%, p=0.0002].3,13,25
However, in the current study, extended DAPT did not sig-
nificantly increase the risk of major bleeding after propensity 
matching (2.1% vs. 1.2%, p=0.07). Therefore, extended DAPT 
could be used in patients at high thrombotic risk without ex-
cessively increasing the risk of major bleeding. In clinical prac-
tice, the duration of DAPT may be tailored after careful evalu-
ation of both bleeding and ischemic risk, while taking into 
consideration the clinical presentation, lesion complexity, and 
procedural factors. 
The strength of this study lies in its use of population-based, 
real-world registries. However, this study had several limita-
tions. First, this was a retrospective analysis of registry data. 
Second, since the current study included only patients who 
did not experience a major event during 3 years after PCI and 
were compliant with the designated therapy, the study results 
were only relevant to patients who achieved that milestone. In 
Fig. 3. Subgroup analyses. HRs for NACE from Cox regression models investigating extended-DAPT versus guideline-DAPT are shown for patient sub-
groups. DAPT, dual antiplatelet therapy; HR, hazard ratio; CI, confidence interval; NACE, net adverse clinical events.
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All patients 16 677 28 1149 0.96 (0.52–1.78)
Bifurcation
Yes 4 209 8 340 0.80 (0.24–2.68)
No 12 468 20 809 1.02 (0.50–2.09)
Acute coronary syndrome
Yes 9 304 14 446 0.94 (0.41–2.17)
No 7 373 14 703 0.93 (0.37–2.30)
Stent diameter (mm)
≤3.0 9 404 15 569 0.85 (0.37–1.94)
>3.0 7 273 13 580 1.09 (0.44–2.75)
Total stentlength (mm)
≥28 12 398 21 633 0.91 (0.45–1.85)
<28 4 279 7 516 1.07 (0.31–3.65)
Stent generation
First 11 408 11 334 0.82 (0.36–1.90)
Second 5 269 17 815 0.88 (0.32–2.38)
Sex
Male 12 459 23 779 0.68 (0.43–1.73)
Female 4 218 5 370 1.42 (0.38–5.30)
Hypertension
Yes 11 426 22 736 0.85 (0.41–1.76)
No 5 251 6 413 1.37 (0.42–4.50)
Diabetes mellitus
Yes 6 212 14 351 0.70 (0.27–1.83)
No 10 465 14 798 1.22 (0.54–2.74)
Multi-vessel disease
Yes 3 22 1 23 1.06 (0.51–2.21)
No 13 655 27 1126 0.73 (0.23–2.33)
   p value
 Favors Favors for 










0                     1                                           3
HR (95% CI)
604
Determinants and Outcomes of Extended DAPT
https://doi.org/10.3349/ymj.2020.61.7.597
interpreting the results of the current study, the group of sub-
jects should not be expanded, and the results should be inter-
preted with caution. Third, neither medication adherence nor 
tolerability was evaluated. Fourth, as the patients enrolled in 
this study were event-free for 3 years, there was a possibility that 
the patients at low risk of bleeding or cardiovascular events 
were enrolled. Fifth, patients who had used DAPT for >3 years 
were classified into the extended-DAPT group, but this classi-
fication was arbitrary. Careful attention would be needed for 
interpretation of the current results. Notwithstanding, 86.4% of 
the patients in the extended-DAPT group actually used DAPT 
for more than 5 years. Sixth, the classification of the guideline, 
intermediate, and extended-DAPT groups may be an arbi-
trary classification. The guideline-DAPT group was developed 
for comparison with the extended-DAPT group, and was clas-
sified according to the duration of DAPT use. Seventh, we 
could not achieve perfect matching or control of all of the con-
founding variables, even though we conducted propensity 
score matching analysis to reduce bias. However, we were able 
to exclude all of the extremes in each group. Finally, this study 
only included thienopyridine P2Y12 inhibitors. Therefore, ad-
ditional studies comparing the extended DAPT using new anti-
platelet agents, such as ticagrelor and prasugrel, with standard 
DAPT should be performed to further guide clinical practice. 
In conclusion, the significant predictors for the use of extend-
ed DAPT for more than 3 years were ACS, bifurcation, small 
stent diameter, long length of DES, and first-generation DES 
in the real world. In patients undergoing PCI, indefinite use of 
DAPT did not show superiority in reducing the clinical events 
compared to the guideline-DAPT. Moreover, major bleeding 
rates were similar. Notably, however, in patients who were treat-
ed with first-generation DESs, extended-DAPT was associated 
with significantly lower MACCE rates compared to guideline-
DAPT. 
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